NCT01497873 2018-12-27
A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung Cancer
Chong Kun Dang Pharmaceutical
Phase 2 Completed
Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical
Chong Kun Dang Pharmaceutical
Yonsei University
National Cancer Center, Korea